Planttech's carob concentrate has shown remarkable results in improving insulin sensitivity in individuals with elevated glucose levels, according to a recent study conducted by researchers at the University of Murcia (UCAM) and the Biomedical Research Institute of Murcia, Spain. This breakthrough finding not only advances our understanding of carob extract's effects but also highlights its potential in diabetes disease prevention. The study, published in Nutrients, presents a randomized double-blind placebo-controlled human trial involving 52 subjects with prediabetes, a condition characterized by elevated blood glucose levels and a high risk of progressing to Type 2 diabetes mellitus (T2DM).
The key to Planttech's LVLD extract lies in its standardized inositols from carob pods, including D-pinitol, myo-inositol, and D-chiro-inositol. According to Planttech CEO Ignacio Zauldua, the clinically relevant effects are attributed to the synergistic interaction between D-pinitol and the broader spectrum of naturally occurring carob bioactives within the syrup matrix, creating an 'entourage effect' that includes polyphenols and micronutrient cofactors. This entourage effect is what sets Planttech's product apart and contributes to its impressive results.
The study's findings were statistically significant, showing improvements in HbA1c (glycated hemoglobin) and glucose levels in the experimental group compared to the placebo group. Fasting serum insulin results indicated significant decreases in the experimental group, with insulin indexes improving significantly. The Oral Glucose Tolerance Test (OGTT) further confirmed these improvements, showing enhanced glucose and insulin metabolism in the experimental group. Importantly, the product was well-tolerated, with no adverse effects reported.
The mechanism of action behind carob extract's effectiveness is multifaceted. Aqueous extracts of carob leaves have been shown to reduce glucose absorption in both in vivo and in vitro settings. Additionally, methanolic extracts of carob pods exhibit inhibitory effects against amylase and glucosidase in streptozotocin-nicotinamide-induced diabetic rat models. These findings, along with other experimental studies, suggest that carob-derived products can effectively inhibit key enzymes involved in carbohydrate digestion, thereby improving glycemic control.
The high content of D-pinitol in carob is particularly noteworthy, as it possesses insulin-mimetic and insulin-sensitizing mechanisms. This compound's ability to mimic and sensitize insulin receptors is a significant factor in the product's effectiveness. Zauldua's team plans to expand their clinical program, conducting larger and longer-duration studies to further explore the potential of carob extract in prediabetic and metabolically challenged populations. They are also interested in investigating the broader carob bioactive matrix and the entourage effect's role in supporting glucose regulation and insulin sensitivity.
The growing consumer awareness of glucose management and postprandial response, coupled with the increasing interest from companies seeking evidence-backed ingredients for healthier glucose metabolism, positions carob extract as a promising natural solution. Planttech's carob concentrate, with its scientifically-backed mechanism of action and positive clinical trial results, is poised to play a significant role in the metabolic health market, offering a natural and effective approach to diabetes disease prevention and management.
